RDHL
Redhill Biopharma·NASDAQ
--
--(--)
--
--(--)
1.05 / 10
Underperform
RDHL's fundamental score is 1.05/10, with key weaknesses in revenue growth (YoY +58.59% but grouped in lower quartile) and coverage ratios. Only Inventory Turnover and Interest Coverage (EBIT/Interest) register positive factors, while Net Profit/Total Profit is at maximum score. The profile suggests operational inefficiencies and limited profitability, aligning with an underperform stance.
Analysis Checks(3/5)
Total operating revenue (YoY growth rate %)
Value58.59
Score0/3
Weight40.90%
1M Return-6.54%
Value58.59
Score0/3
Weight40.90%
1M Return-6.54%
Interest coverage ratio (EBIT / Interest expense) (%)
Value27.60
Score2/3
Weight9.11%
1M Return-1.25%
Value27.60
Score2/3
Weight9.11%
1M Return-1.25%
Net profit / Total profit (%)
Value100.00
Score2/3
Weight7.19%
1M Return-0.98%
Value100.00
Score2/3
Weight7.19%
1M Return-0.98%
Inventory turnover ratio
Value0.47
Score2/3
Weight8.75%
1M Return-1.23%
Value0.47
Score2/3
Weight8.75%
1M Return-1.23%
Operating revenue (YoY growth rate %)
Value58.59
Score0/3
Weight34.04%
1M Return-5.31%
Value58.59
Score0/3
Weight34.04%
1M Return-5.31%
Total operating revenue (YoY growth rate %)
Value58.59
Score0/3
Weight40.90%
1M Return-6.54%
Value58.59
Score0/3
Weight40.90%
1M Return-6.54%
Inventory turnover ratio
Value0.47
Score2/3
Weight8.75%
1M Return-1.23%
Value0.47
Score2/3
Weight8.75%
1M Return-1.23%
Interest coverage ratio (EBIT / Interest expense) (%)
Value27.60
Score2/3
Weight9.11%
1M Return-1.25%
Value27.60
Score2/3
Weight9.11%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value58.59
Score0/3
Weight34.04%
1M Return-5.31%
Value58.59
Score0/3
Weight34.04%
1M Return-5.31%
Net profit / Total profit (%)
Value100.00
Score2/3
Weight7.19%
1M Return-0.98%
Value100.00
Score2/3
Weight7.19%
1M Return-0.98%
Is RDHL undervalued or overvalued?
- RDHL scores 1.05/10 on fundamentals and holds a Premium valuation at present. Backed by its 0.00% ROE, -97.52% net margin, -0.59 P/E ratio, -1.24 P/B ratio, and 100.00% earnings growth, these metrics solidify its Underperform investment rating.
